Background: Alterations in the phosphatase and tensin homolog (PTEN) are correlated with tumor progression. Downregulation of PTEN is related to drug resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the prognostic significance of PTEN in patients with NSCLC and its correlation with EGFR. Methods: Two hundred eighty eight surgically resected NSCLC samples, including 168 adenocarcinomas (ADCs), 99 squamous cell carcinomas (SCCs) and 21 other NSCLCs were analyzed for the PTEN. The results were correlated with other clinicopathological variables including EGFR amplification and mutation. Results: Loss of PTEN was detected in 42.4% of NSCLCs, specifically 28.6% of ADCs, 66.7% of SCCs, and 38.1% of others. Loss of PTEN was significantly associated with SCC, smoking, male gender, and higher stage. In a multivariate analysis, loss of PTEN was significantly associated with short progression-free survival (p= 0.037). No association between PTEN and EGFR was observed. Conclusions: These results suggest that loss of PTEN results in shorter progression-free survival in patients with NSCLC, and loss of PTEN is more associated with SCC, smoking, male gender, and higher T stage by the 7th tumor, node and metastasis staging system but not EGFR status.
Lung cancer is a highly aggressive disease and a major cause of cancer deaths worldwide. 1 Although an early diagnosis and surgery are considered the choice treatment, many patients with lung cancer present at the advanced stage. Many studies have been conducted regarding the molecular mechanisms underlying lung cancer to develop new effective therapeutic agents. 2, 3 Growth factor receptor signaling pathways constitute an important mediator for tumor growth and proliferation in nonsmall cell lung cancer (NSCLC). The tumor suppressor phosphatase and tensin homolog (PTEN), located at 10q23, encodes a cytoplasmic protein with a protein tyrosine phosphatase domain, has extensive homology to tensin, 4 and is an important negative regulator of cell survival signal transduction along this pathway. The PTEN protein acts by dephosphorylating phosphatidylinositol (3, 4, 5)-triphosphate and negatively regulates the phosphatidylinositol 3-kinase/Akt (PI3K/Akt) pathway. 5 Various alterations including mutations, 6 homozygous deletions, 7 promoter hypermethylation, 8 and microsatellite instability of the PTEN gene influence the negative regulation of the PI3K/Akt signaling pathway, 9 a downstream survival signal activated by epidermal growth factor receptor (EGFR).
Signaling pathways activated by EGFRs are important in lung carcinogenesis, and activating mutations in the EGFR gene in patients with lung adenocarcinoma (ADC) is associated with an
Loss of PTEN Expression is an Independent Poor Prognostic Factor in
Non-small Cell Lung Cancer excellent clinical response to EGFR-tyrosine kinase inhibitors (TKIs). 10 However, patients often experience a tumor recurrence or distant metastasis after treatment with EGFR-TKIs, even when the tumors are initially highly sensitive. 11 Recently, downregulation of PTEN has been reported as one of the molecular mechanisms underlying resistance to EGFR-TKIs. 12 In this study, we investigated whether loss of PTEN expression is correlated with clinicopathological parameters or correlated with EGFR gene status in patients with surgically resected primary NSCLC.
MATERIALS AND METHODS

Patients and specimens
From May 2003 to December 2006, 288 consecutive lung cancer patients, who underwent a surgical resection at the Seoul National University Bundang Hospital, were compiled. Tumors from patients who died from causes other than lung carcinoma or recurrent or metastatic tumors were excluded. None of the patients enrolled in this study had received preoperative neoadjuvant chemotherapy (CTx) or irradiation. Smoking status was defined as never-smokers (<100 lifetime cigarettes). Clinical and pathological data were retrieved from the medical records. This study was approved by the Institutional Review Board.
The patients consisted of 206 (71.5%) men and 82 (28.5%) women with a mean age of 62.6 years (range, 21 to 84 years), and the mean tumor size was 3.5 cm (standard deviation, 19.83; range, 0.4 to 16 cm). These patients underwent surgical treatment (wedge resection, n=12; segmentectomy, n=5; lobectomy, n=235; bilobectomy, n=16; and pneumonectomy, n=20). Of these, 172 and 84 patients received postoperative adjuvant CTx and postoperative adjuvant radiation therapy, respectively. Among them, 37 patients received additional EGFR-TKIs such as gefitinib or erotinib. EGFR mutations and EGFR gene copy number data were available in 55 and 278 patients, respectively. 13 Of these, the correlation between EGFR gene copy number was assessed by chromogenic in situ hybridization (CISH), as previously described. 13 Hematoxylin and eosin (H&E) stained slides were reviewed in each case to confirm the original diagnosis. Two pathologists (SBY and JHC) independently reviewed these slides to select the most representative sections based on World Health Organization criteria. 14 stage IV tumors according to the 6th edition of the AJCC/UICC staging system. The median follow-up period was 44 months for progression-free survival and 56 months for cancer-specific survival (range, 1 to 84 months).
Construction of a tissue microarray (TMA)
The most representative tumor area was carefully marked on H&E stained slides of sample tissue cores (2 mm in diameter) from formalin fixed and paraffin embedded (FFPE) tissue blocks. A representative core from each tumor was included in the TMA block.
PTEN immunohistochemistry (IHC)
For the IHC analysis, 4 µm thick sections were cut from the TMA blocks and deparaffinized in xylene and rehydrated in a graded alcohol series. The following steps were performed by the Benchmark ® XT Slide Autostaining System (Ventana Medical Systems, Tucson, AZ, USA). Antigen retrieval was performed using a microwave in pH 6.0 citrate-phosphate buffer. IHC staining was conducted using a rabbit monoclonal antibody against PTEN (1:50, Y184, Epitomics, Burlingame, CA, USA). PTEN immunoreactivity was examined based on cytoplasmic staining using a semi-quantitative scoring method into four categories as follows: 0, negative; 1, 1-25% positive; 2, 26-50% positive; and 3, >50% positive in tumor cells. When the staining was equal or less than 50% (score 0, 1, or 2), it was considered as loss of PTEN expression. 9 The interpretation of PTEN staining was independently evaluated by two pathologists (SBY and JHC). In the rare instance of a discrepancy in judgment, agreement was reached by discussion at a multiheadmicroscope.
EGFR mutational analysis
The EGFR mutational analysis at exons 18-21 was performed by polymerase chain reaction (PCR) amplification and a direct DNA sequencing method. 16 The PCR products were analyzed with a Big Dye Terminator Version 3.1 Cycle Sequencing kit (Applied Biosystems, Foster, CA, USA) and sequencing data were obtained with an ABI PRISM 3100 DNA Analyzer (Applied Biosystems).
EGFR CISH
EGFR gene copy number status was examined using the ZytoDotSPEC EGFR Probe Kit protocol (ZytoVision, Bremerhaven, Germany). FFPE tissues were deparaffinized (dewaxed/ proteolysis). The next procedures were performed according to the manufacturer's instructions. 13, 17 The signals of 200 nonoverlapping tumor cells were determined. EGFR gene copy number was divided into CISH-negative and CISH-positive groups. Four or more dots per nucleus in ≥40% of tumor cells or the presence of tight gene clusters in ≥10% of tumor cells was confirmed as CISH-positive.
13,17
Statistical analysis
Fisher's exact test or Pearson's chi-square test were used to evaluate the relationships among the clinicopathological factors, EGFR status, and PTEN expression. The Kaplan-Meier method was used to obtain survival curves, and the log-rank test was used for statistical significance. A multivariate survival analysis was performed using the Cox proportional hazard model. Statistical significance was defined as p<0.05. All analyses were performed using SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA). mal cells (Fig. 1) (Table 1) . Other clinicopathological variables, including age, performance status, pleural invasion, and lymphovascular invasion showed no correlation with the loss of PTEN expression. No significant association was found between PTEN expression loss and a gain in EGFR copy number (amplification or high polysomy) or EGFR mutation.
Survival analysis
At the time of analysis, the number of cancer-specific deaths was 91 (31.6%). Cancer-specific survival was highly correlated with p-stage (p<0.000). PTEN expression showed no association with cancer-specific survival. However, loss of PTEN expression resulted in significantly shorter progression-free survival than that in the intact PTEN expression group (Fig. 2) . A Values are presented as number (%). CISH, chromogenic in situ hybridization.
multivariate analysis using the Cox proportional hazard model was performed to evaluate whether PTEN loss was an independent predictor in patients with NSCLC. (Table 2) .
Correlation among PTEN expression and EGFR copy number and EGFR gene mutation
The data for EGFR copy number and EGFR gene mutation were available in 278 and 55 patients, respectively, and the results were correlated with PTEN expression. PTEN expression was not associated with any EGFR status. The percentage of intact PTEN tended to be higher than the loss of PTEN in the EGFR copy number and EGFR mutated groups (60.3% vs 39.7%; 63.3% vs 36.7%); however, the difference was not statistically significant (p=0.396, and p=0.311, respectively) (Table 3).
DISCUSSION
The results of this study demonstrate that loss of PTEN expression was correlated with shorter progression-free survival, suggesting that loss of PTEN expression is an important prognostic predictor of NSCLC.
The loss of PTEN expression is frequent in patients with NSCLC and is associated with shortened survival rates. 18 Jiang and Wang 19 reported that PTEN expression is lower in tumor components compared with that in normal tissue in patients with NSCLC. The lack of PTEN associated with PI3K and Akt upregulation results in tumor development and a poor prognosis in patients with NSCLC. 20, 21 Liao et al. 22 suggested that low PTEN expression is correlated with tumorigenesis and lymph node metastasis, but no association with pathological type or tumor differentiation was found. These results were similar to previous studies indicating that the loss of PTEN expression is an important event associated with tumor recurrence or progression. Furthermore, loss of PTEN expression was frequently associated with SCC histology, male gender, smoking, larger tumor size, and high p-stage according to the 7th edition of the AJCC/UICC staging system but not the 6th edition of the staging system. These results suggest that the new staging system may reflect prognostic implications of validated biomarker better than the 6th edition staging system. 23 The association between PTEN loss of expression, male gender, and smoking appeared to be affected by frequent PTEN loss in the SCC histology.
PTEN expression was not associated with EGFR status, such as EGFR copy number or mutation. PTEN is closely involved in the EGFR signaling pathway and its loss of expression in patients with NSCLC is related to the EGFR-TKI drug resistance mechanism and activation of PI3K/Akt/mammalian target of rapamycin signaling. 12, 18 It has been proposed that down regulation of PTEN and Akt activation are associated with erlotinib resistance. 24 Although we observed a tendency for more frequent PTEN protein expression than PTEN loss in the EGFR mutation positive cases (64.7% vs 35.3%), no statistical significance was found (p=0.311). Thus, it is difficult to draw any biological meaning from this result due to the small amount of available EGFR mutation data (n=55). Because the number of patients treated with EGFR-TKIs was also small and because the follow-up duration was short to evaluate the relationship between drug response and PTEN expression loss, it was impossible to investigate the role of PTEN on EGFR-TKI drug responsiveness in this cohort. Further study with a longer follow-up is required to disclose clinical evidence of a relationship between PTEN loss of expression and EGFR-TKIs resistance.
In summary, our study demonstrated that loss of PTEN expression results in shorter progression-free survival in patients with NSCLC, and that loss of PTEN expression was more significantly associated with SCC than ADC, smoking, male gender, and higher T stage but not EGFR status. Furthermore, loss of PTEN expression was more correlated with p-stage using the 7th edition tumor, node and metastasis staging system than the 6th edition staging system.
